‘Nimesulide’ may come with warning label
New Delhi: Makers of anti-inflammatory drug nimesulide will be required to display cautionary warning labels that the drug be used only as a second-line treatment for patients 12 years and above after all the first-line options are exhausted. The market for nimesulide formulations in India is about ₹500 crore, expanding at 11% over the past…